Amphiphile

Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, November 9, 2023

R&D Expense: R&D expense for the third quarter of 2023 was $7.3 million, compared to $4.6 million for the third quarter of 2022.

Key Points: 
  • R&D Expense: R&D expense for the third quarter of 2023 was $7.3 million, compared to $4.6 million for the third quarter of 2022.
  • G&A Expense: G&A expense for the third quarter of 2023 was $3.5 million, compared to $1.2 million for the third quarter of 2022.
  • Net Loss and Net Loss per Share: Net loss for the third quarter of 2023 was $10.7 million, compared to $7.2 million for the third quarter of 2022.
  • Net loss per share for the third quarter of 2023 was $1.27 compared to $22.67 for the third quarter of 2022.

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting

Retrieved on: 
Friday, November 3, 2023

The strength of the induced T cell response correlated with a significantly reduced risk of relapse and death.

Key Points: 
  • The strength of the induced T cell response correlated with a significantly reduced risk of relapse and death.
  • The data will be presented at the Society for Immunotherapy of Cancer 38th Annual Meeting (SITC 2023) taking place at the San Diego Convention Center in San Diego, CA and virtually from November 1-5, 2023.
  • ELI-002 2P consists of 2 Amph-modified mKRAS peptide antigens, Amph-G12D and Amph-G12R (Amph-Peptides 2P), and an Amph-modified immune-stimulatory oligonucleotide adjuvant (Amph-CpG-7909).
  • 90% of immune responders had T cell responses to ≥ two mKRAS antigens, with 35% responding to all seven mKRAS antigens evaluated.

Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Friday, August 11, 2023

BOSTON, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate and clinical updates.

Key Points: 
  • BOSTON, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate and clinical updates.
  • R&D Expense: R&D expense for the second quarter of 2023 was $4.9 million, compared to $5.0 million for the second quarter of 2022.
  • G&A Expense: G&A expense for the second quarter of 2023 was $2.8 million, compared to $1.2 million for the second quarter of 2022.
  • Net loss per share for the second quarter of 2023 was $2.61 compared to $23.20 for the second quarter of 2022.

Elicio Therapeutics Announces Publication of Preclinical Data in Science Translational Medicine Demonstrating the AMP Platform Promotes Uptake of Intranasal Vaccine in the Mucosa Amplifying Immune Response

Retrieved on: 
Tuesday, October 4, 2022

BOSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced the publication of preclinical data from the research laboratory of Dr. Darrell Irvine at the Massachusetts Institute of Technology (MIT), demonstrating Elicio’s Amphiphile (AMP) platform conjugated to protein antigens promotes uptake in the nasal mucosa and amplifies immune responses after intranasal immunization. Immunization through airway surfaces has proven challenging due to poor vaccine uptake across these linings. The data presented here represents a promising strategy to promote mucosal immunity against HIV, SARS-CoV-2, and other infectious diseases. The data was published in Science Translational Medicine and can be accessed here.

Key Points: 
  • The data was published in Science Translational Medicine and can be accessed here .
  • Delivery of vaccine components across mucosal barriers has been a major challenge for mucosal vaccine development.
  • This data demonstrates that AMP-modification can improve vaccine uptake across the nasal mucosa via interactions with albumin and the neonatal Fc receptor known as the mucosal gateway.
  • The findings are encouraging for the translational potential of this approach to induce antibodies in a variety of mucosal sites after intranasal immunization.

Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines

Retrieved on: 
Tuesday, September 20, 2022

We are excited to receive the grant from GIRF and look forward to broadening our pipeline by developing ELI-007 and ELI-008 to target these key cancer mutations.

Key Points: 
  • We are excited to receive the grant from GIRF and look forward to broadening our pipeline by developing ELI-007 and ELI-008 to target these key cancer mutations.
  • In preclinical models, we have observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability.
  • Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases.
  • Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.

Elicio Therapeutics Announces Publication of Preclinical Data on ELI-005, a Lymph Node-Targeted Amphiphile Vaccine Against SARS-CoV-2

Retrieved on: 
Wednesday, September 7, 2022

BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) --  Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced the publication of data from a preclinical study evaluating ELI-005, Elicio’s Amphiphile (AMP) adjuvant, AMP-CpG, admixed with the SARS-CoV-2 Spike receptor binding domain (RBD) immunogen, as a lymph node-targeted protein subunit vaccine. The results show ELI-005 administration safely promotes robust cellular and humoral immunity through potent, targeted engagement of the lymph nodes in both mice and non-human primates (NHPs). Additionally, these data demonstrate the promise of lymph node adjuvant-targeting to coordinate innate immunity and the generation of robust adaptive responses that are critical for vaccine efficacy. These results were published in the preprint server, bioRxiv, and can be accessed here.

Key Points: 
  • Additionally, these data demonstrate the promise of lymph node adjuvant-targeting to coordinate innate immunity and the generation of robust adaptive responses that are critical for vaccine efficacy.
  • In preclinical models, we have observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability.
  • Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases.
  • Elicio is engineering lymph node targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.

Elicio Therapeutics Presents Preclinical Data on AMP-CpG Adjuvant in Combination with EBV Vaccine at the 2022 Keystone Symposia: Viral Immunity: Basic Mechanisms and Therapeutic Applications

Retrieved on: 
Wednesday, July 6, 2022

The data was presented at the 2022 Keystone Symposia on Viral Immunity Basic Mechanisms and Therapeutic Applications virtually and in-person at the Keystone Resort in Keystone, CO from June 29-July 2, 2022.

Key Points: 
  • The data was presented at the 2022 Keystone Symposia on Viral Immunity Basic Mechanisms and Therapeutic Applications virtually and in-person at the Keystone Resort in Keystone, CO from June 29-July 2, 2022.
  • EBV is a herpesvirus responsible for the well-known mononucleosis infections (mono) and has also been implicated in multiple lymphoid and epithelial cancers.
  • EBV targets both B cells and epithelial cells and utilizes their molecular machinery to replicate the viral genome.
  • In preclinical models, we have observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability.

Elicio Therapeutics Presents Preclinical Data on its Lymph Node-Targeted SARS-CoV-2 Amphiphile Vaccine, ELI-005, at the 2022 Keystone Symposia on Viral Immunity: Basic Mechanisms and Therapeutic Applications

Retrieved on: 
Wednesday, July 6, 2022

ELI-005, containing the lymph node-targeted Amphiphile vaccine adjuvant AMP-CpG, induced potent, comprehensive and persistent innate immune responses in draining lymph nodes in mice.

Key Points: 
  • ELI-005, containing the lymph node-targeted Amphiphile vaccine adjuvant AMP-CpG, induced potent, comprehensive and persistent innate immune responses in draining lymph nodes in mice.
  • The robust immune responses generated by ELI-005 suggest that it may enhance broad protection against new variants of concern.
  • We are pleased to present updated data from ongoing preclinical work in mice and non-human primates with ELI-005, our lymph node-targeting AMP-vaccine against SARS-CoV-2.
  • In preclinical models, we have observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability.

Elicio Therapeutics Announces Publication of Preclinical Data Showing AMP-Peptide Vaccine in Combination with TCR-T Cell Therapy Enhances Anti-Tumor Function and Eradicates Solid Tumors

Retrieved on: 
Monday, May 23, 2022

Dylan Drakes and Peter DeMuth, with Elicio colleagues, were published in the preprint server, bioRxiv, and can be found here .

Key Points: 
  • Dylan Drakes and Peter DeMuth, with Elicio colleagues, were published in the preprint server, bioRxiv, and can be found here .
  • T cell receptor (TCR)-modified T cell therapies have historically shown promise but challenges to clinical efficacy against solid tumors persist.
  • Often, suboptimal clinical performance can be attributed to insufficient in vivo persistence of current treatments and tumor antigen escape.
  • In preclinical models, we have observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability.

Elicio Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate ELI-002 in Combination with Libtayo® (cemiplimab) in KRAS-Driven Tumors

Retrieved on: 
Monday, May 16, 2022

The study, which is expected to begin in 2023, will be conducted by Elicio Therapeutics.

Key Points: 
  • The study, which is expected to begin in 2023, will be conducted by Elicio Therapeutics.
  • Were investigating ELI-002s immune education in combination with the ability of Libtayo to block PD-1 and potentially activate the ELI-002-induced T cells to target cancers.
  • ELI-002 includes mutated KRAS peptides that are delivered directly to the lymph nodes, the schoolhouse of the immune system.
  • Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases.